Vitiligo Treatment Impact score (VITs): development and validation of a vitiligo burden of treatment questionnaire using the ComPaRe Vitiligo e‐cohort

Shourick, Jason; Sénéschal, Julien; Andreu, Nicolas; Meurant, Jean-Marie; Pane, Isabelle; Ravaud, Philippe; Tran, Viet‐Thi; Ezzedine, Khaled

doi:10.1111/jdv.17742

Cited by 4 publications

(5 citation statements)

References 48 publications

(81 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 The complexity of treatment regimens (including time taken to treat and experience satisfactory results) is expected to compound the burden experienced by patients and their caregivers. 155 Additionally, the likelihood of repigmentation is dependent on lesion location, with facial lesions being more responsive to treatment than lesions on the hands and feet. 156,157 It is also generally accepted that patient satisfaction is associated with nearcomplete (≥80%) repigmentation.…”

Section: Discussionmentioning

confidence: 99%

“…Repigmentation of vitiligo lesions is typically a slow process, and psychosocial stress together with previous treatment failure can affect long‐term treatment adherence 4 . The complexity of treatment regimens (including time taken to treat and experience satisfactory results) is expected to compound the burden experienced by patients and their caregivers 155 . Additionally, the likelihood of repigmentation is dependent on lesion location, with facial lesions being more responsive to treatment than lesions on the hands and feet 156,157 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The humanistic burden of vitiligo: a systematic literature review of quality‐of‐life outcomes

Picardo

Huggins

Jones

et al. 2022

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

Despite historical mischaracterization as a cosmetic condition, patients with the autoimmune disorder vitiligo experience substantial quality-of-life (QoL) burden. This systematic literature review of peer-reviewed observational and interventional studies describes comprehensive evidence for humanistic burden in patients with vitiligo. PubMed, EMBASE, Scopus and the Cochrane databases were searched through February 10, 2021, to qualitatively assess QoL in vitiligo. Two independent reviewers assessed articles for inclusion and extracted data for qualitative synthesis. A total of 130 included studies were published between 1996 and 2021. Geographical regions with the most studies were Europe (32.3%) and the Middle East (26.9%). Dermatology-specific instruments, including the Dermatology Life Quality Index (DLQI; 80 studies) and its variants for children (CDLQI; 10 studies) and families (FDLQI; 4 studies), as well as Skindex instruments (Skindex-29, 15 studies; Skindex-16, 4 studies), were most commonly used to measure humanistic burden. Vitiligospecific instruments, including the Vitiligo-specific QoL (VitiQoL; 11 studies) instrument and 22-item Vitiligo Impact Scale (VIS-22; 4 studies), were administered in fewer studies. Among studies that reported total scores for the overall population, a majority revealed moderate or worse effects of vitiligo on patient QoL (DLQI, 35/54 studies; Skindex, 8/8 studies; VitiQoL, 6/6 studies; VIS-22, 3/3 studies). Vitiligo also had a significant impact on the QoL of families and caregivers; 4/4 studies reporting FDLQI scores indicated moderate or worse effects on QoL. In general, treatment significantly (P < 0.05) improved QoL, but there were no trends for types or duration of treatment. Among studies that reported factors significantly (P ≤ 0.05) associated with reduced QoL, female sex and visible lesions and/or lesions in sensitive areas were most common. In summary, vitiligo has clinically meaningful effects on the QoL of patients, highlighting that greater attention should be dedicated to QoL decrement awareness and improvement in patients with vitiligo.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The humanistic burden of vitiligo: a systematic literature review of quality‐of‐life outcomes

Picardo

Huggins

Jones

et al. 2022

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Vitiligo is a common hypopigmentary dermatosis characterized by patches of depigmentation affecting approximately 0.1%–2.0% of the global population 1–5 . Although the disease does not directly cause physical impairment, it influences patients' quality of life and psychological health 6–8 …”

Section: Introductionmentioning

confidence: 99%

“…[1][2][3][4][5] Although the disease does not directly cause physical impairment, it influences patients' quality of life and psychological health. [6][7][8] Vitiligo treatment remains a challenge for dermatologists and is often unsatisfactory. Many options have been proposed and are currently available, including traditional pharmacological approaches such as topical and systemic corticosteroids, topical calcineurin phosphatase inhibitors, vitamin D derivatives, and phototherapy.…”

mentioning

confidence: 99%

Target area treatment ratio of varied lesions in the cultured pure melanocyte transplantation repigmentation of vitiligo: A retrospective study

Lin,

Wang,

Zheng

et al. 2024

The Journal of Dermatology

View full text Add to dashboard Cite

Autologous cultured pure melanocyte transplantation (CMT) can be utilized to treat stable vitiligo cases, but clinical data are insufficient to improve its efficacy. To evaluate the influence of various factors on the therapeutic effect of CMT, this single‐center retrospective study enrolled stable vitiligo patients who underwent CMT between 2009 and 2020. Univariate and multivariable analysis were used to determine the factors affecting the outcome of repigmentation. The study included 491 patients with long‐term follow‐up data (6–120 months). It was found that 69.7% of patients achieved an excellent re‐color effect and 18.4% achieved a good re‐color effect. There were statistically significant differences in pigmentation between patients with stable disease course, vitiligo type, and lesion site. Overall, a significant positive correlation between the target area treatment ratio of varied lesions and the percentage of repigmentation was found. CMT is effective and well tolerated in the treatment of stable vitiligo. Various factors, especially the target area treatment ratio of varied lesions, should be carefully assessed before using CMT. As the target area treatment ratio of varied lesions could further improve the post‐operative repigmentation other than type of vitiligo. This clinic trial was approved by Hangzhou Third People's Hospital (number 2023KA015, national clinical record number MR‐33‐23‐034502).

show abstract

“…Stacks of studies have shown that vitiligo is mostly a complex incorporation of abnormal immune responses, genetic predispositions, oxidative stress, metabolic alterations, and environmental factors [ 1 , 2 ]. The treatment modalities for vitiligo have mostly been nontargeted and generalized like oral or topical immunosuppressants, phototherapy, and surgical methods with limited efficacy and potential side effects [ 4 , 5 ]. There has been an emergence of innovative targeted therapies aimed at limiting disease progression and achieving repigmentation with a good safety profile based on a better understanding of the pathophysiology [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Pharmacological inhibition of demethylzeylasteral on JAK-STAT signaling ameliorates vitiligo

et al. 2023

View full text Add to dashboard Cite

Background The activation of CD8+ T cells and their trafficking to the skin through JAK-STAT signaling play a central role in the development of vitiligo. Thus, targeting this key disease pathway with innovative drugs is an effective strategy for treating vitiligo. Natural products isolated from medicinal herbs are a useful source of novel therapeutics. Demethylzeylasteral (T-96), extracted from Tripterygium wilfordii Hook F, possesses immunosuppressive and anti-inflammatory properties. Methods The efficacy of T-96 was tested in our mouse model of vitiligo, and the numbers of CD8+ T cells infiltration and melanocytes remaining in the epidermis were quantified using whole-mount tail staining. Immune regulation of T-96 in CD8+ T cells was evaluated using flow cytometry. Pull-down assay, mass spectrum analysis, molecular docking, knockdown and overexpression approaches were utilized to identify the target proteins of T-96 in CD8+ T cells and keratinocytes. Results Here, we found that T-96 reduced CD8+ T cell infiltration in the epidermis using whole-mount tail staining and alleviated the extent of depigmentation to a comparable degree of tofacitinib (Tofa) in our vitiligo mouse model. In vitro, T-96 decreased the proliferation, CD69 membrane expression, and IFN-γ, granzyme B, (GzmB), and perforin (PRF) levels in CD8+ T cells isolated from patients with vitiligo. Pull-down assays combined with mass spectrum analysis and molecular docking showed that T-96 interacted with JAK3 in CD8+ T cell lysates. Furthermore, T-96 reduced JAK3 and STAT5 phosphorylation following IL-2 treatment. T-96 could not further reduce IFN-γ, GzmB and PRF expression following JAK3 knockdown or inhibit increased immune effectors expression upon JAK3 overexpression. Additionally, T-96 interacted with JAK2 in IFN-γ-stimulated keratinocytes, inhibiting the activation of JAK2, decreasing the total and phosphorylated protein levels of STAT1, and reducing the production and secretion of CXCL9 and CXCL10. T-96 did not significantly inhibit STAT1 and CXCL9/10 expression following JAK2 knockdown, nor did it suppress upregulated STAT1-CXCL9/10 signaling upon JAK2 overexpression. Finally, T-96 reduced the membrane expression of CXCR3, and the culture supernatants pretreated with T-96 under IFN-γ stressed keratinocytes markedly blocked the migration of CXCR3+CD8+ T cells, similarly to Tofa in vitro. Conclusion Our findings demonstrated that T-96 might have positive therapeutic responses to vitiligo by pharmacologically inhibiting the effector functions and skin trafficking of CD8+ T cells through JAK-STAT signaling.

show abstract

Vitiligo Treatment Impact score (VITs): development and validation of a vitiligo burden of treatment questionnaire using the ComPaRe Vitiligo e‐cohort

Cited by 4 publications

References 48 publications

The humanistic burden of vitiligo: a systematic literature review of quality‐of‐life outcomes

The humanistic burden of vitiligo: a systematic literature review of quality‐of‐life outcomes

Target area treatment ratio of varied lesions in the cultured pure melanocyte transplantation repigmentation of vitiligo: A retrospective study

Pharmacological inhibition of demethylzeylasteral on JAK-STAT signaling ameliorates vitiligo

Contact Info

Product

Resources

About